The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

PURPOSE: In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzumab plus trastuzumab and docetaxel vs. placebo tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Masato, Ohtani, Shoichiro, Nagai, Shigenori E., Takashima, Seiki, Yamaguchi, Miki, Tsuneizumi, Michiko, Komoike, Yoshifumi, Osako, Tomofumi, Ito, Yoshinori, Ikeda, Masahiko, Ishida, Kazushige, Nakayama, Takahiro, Takashima, Tsutomu, Asakawa, Takashi, Matsumoto, Sho, Shimizu, Daisuke, Masuda, Norikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843485/
https://www.ncbi.nlm.nih.gov/pubmed/32920732
http://dx.doi.org/10.1007/s10549-020-05921-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843485/
https://www.ncbi.nlm.nih.gov/pubmed/32920732
http://dx.doi.org/10.1007/s10549-020-05921-x

Ejemplares similares